• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过贝叶斯网络优化药物递送

Drug delivery optimization through Bayesian networks.

作者信息

Bellazzi R

机构信息

Dpt. Informatica e Sistemistica, Universitá di Pavia, Italy.

出版信息

Proc Annu Symp Comput Appl Med Care. 1992:572-8.

PMID:1482938
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2248059/
Abstract

This paper describes how Bayesian Networks can be used in combination with compartmental models to plan Recombinant Human Erythropoietin (r-HuEPO) delivery in the treatment of anemia of chronic uremic patients. Past measurements of hematocrit or hemoglobin concentration in a patient during the therapy can be exploited to adjust the parameters of a compartmental model of the erythropoiesis. This adaptive process allows more accurate patient-specific predictions, and hence a more rational dosage planning. We describe a drug delivery optimization protocol, based on our approach. Some results obtained on real data are presented.

摘要

本文描述了如何将贝叶斯网络与房室模型相结合,用于规划重组人促红细胞生成素(r-HuEPO)给药,以治疗慢性尿毒症患者的贫血。治疗期间患者过去的血细胞比容或血红蛋白浓度测量值可用于调整红细胞生成房室模型的参数。这种自适应过程可以实现更准确的患者特异性预测,从而制定更合理的剂量规划。我们基于我们的方法描述了一种药物递送优化方案。还展示了一些基于实际数据获得的结果。

相似文献

1
Drug delivery optimization through Bayesian networks.通过贝叶斯网络优化药物递送
Proc Annu Symp Comput Appl Med Care. 1992:572-8.
2
Drug delivery optimization through Bayesian networks: an application to erythropoietin therapy in uremic anemia.通过贝叶斯网络优化药物递送:在尿毒症性贫血促红细胞生成素治疗中的应用
Comput Biomed Res. 1993 Jun;26(3):274-93. doi: 10.1006/cbmr.1993.1019.
3
rhEPO treatment of anemia in uremic patients.重组人促红细胞生成素治疗尿毒症患者贫血
Contrib Nephrol. 1990;87:59-67. doi: 10.1159/000419480.
4
Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure.皮下注射低剂量重组人促红细胞生成素对透析前患者肾衰竭进展无影响。
Am J Nephrol. 1995;15(1):10-4. doi: 10.1159/000168795.
5
Mathematical modeling of erythropoietin therapy in uremic anemia. Does it improve cost-effectiveness?尿毒症性贫血中促红细胞生成素治疗的数学模型。它能提高成本效益吗?
Haematologica. 1994 Mar-Apr;79(2):154-64.
6
Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.重组人促红细胞生成素治疗:获得性免疫缺陷综合征贫血的研究性新药方案。总体结果。
Arch Intern Med. 1993 Dec 13;153(23):2669-75.
7
Uremic inhibitors of erythropoiesis: a study during treatment with recombinant human erythropoietin.尿毒症性红细胞生成抑制剂:重组人促红细胞生成素治疗期间的一项研究
Am J Nephrol. 1992;12(1-2):9-13. doi: 10.1159/000168410.
8
[A therapeutical approach by administering reduced glutathione to patients with uremic anemia].[通过给尿毒症贫血患者施用还原型谷胱甘肽的治疗方法]
Hua Xi Yi Ke Da Xue Xue Bao. 2001 Jun;32(2):300-2.
9
A pharmacodynamic model of erythropoietin therapy for uremic anemia.促红细胞生成素治疗尿毒症性贫血的药效学模型。
Clin Pharmacol Ther. 1992 Jan;51(1):76-89. doi: 10.1038/clpt.1992.10.
10
Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
Thromb Haemost. 1991 Dec 2;66(6):638-47.

本文引用的文献

1
Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.药代动力学的贝叶斯个体化:简单实现及与非贝叶斯方法的比较。
J Pharm Sci. 1982 Dec;71(12):1344-8. doi: 10.1002/jps.2600711209.
2
A mathematical model of iron metabolism.铁代谢的数学模型。
J Math Biol. 1982;15(2):173-201. doi: 10.1007/BF00275072.
3
Epoetin: human recombinant erythropoietin.促红细胞生成素:人重组促红细胞生成素。
Clin Pharm. 1989 Nov;8(11):769-82.
4
GAMEES: a probabilistic environment for expert systems.GAMEES:一种用于专家系统的概率环境。
Comput Methods Programs Biomed. 1991 Jul;35(3):177-91. doi: 10.1016/0169-2607(91)90120-i.
5
A pharmacodynamic model of erythropoietin therapy for uremic anemia.促红细胞生成素治疗尿毒症性贫血的药效学模型。
Clin Pharmacol Ther. 1992 Jan;51(1):76-89. doi: 10.1038/clpt.1992.10.